Clicky

DBV Technologies(DBV)

Description: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.


Keywords: Medicine Biopharmaceutical Immunology Immune System Immunotherapy Allergy Crohn's Disease I Diabetes Immunotherapy Products Pertussis Celiac Disease Immunoglobulin E Food Allergies Dbv Technologies Peanut Allergies

Home Page: www.dbv-technologies.com

177-181 Avenue Pierre Brossolette
Montrouge, 92120
France
Phone: 33 1 55 42 78 78


Officers

Name Title
Mr. Daniel Tassé CEO & Director
Mr. Sébastien Robitaille Chief Financial Officer
Dr. Pharis Mohideen Chief Medical Officer
Mr. Pascal Wotling Chief Technical Operations Officer & Chief Quality Officer
Anne Pollak Head of Investor Relations
Ms. Michele F. Robertson Chief Legal Officer
Joseph Becker VP of Global Corp. Communications
Ms. Caroline Daniere Chief HR Officer & Chief of Staff
Dr. Wence Agbotounou Chief Clinical Trial Officer & Sr. VP
Ms. Lucie Mondoulet Sr. VP & Deputy CSO

Exchange: PA

Country: FR : France

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2424
Price-to-Sales TTM: 28.0038
IPO Date:
Fiscal Year End: December
Full Time Employees: 85
Back to stocks